Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shree Ganesh RemediesBOM:540737 -0.05%84 Return-on-Tangible-Asset is 2.16% as of Jun. 2026, which is 87% below its 10-year median of 16.37. GuruFocus rates BOM:540737 with a GF Score™ of 84/100 and a GF Value™ of ₹554.11 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Shree Ganesh Remedies ranks better than 70.21% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Shree Ganesh Remedies's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹44.8 Mil. Shree Ganesh Remedies's average total tangible assets for the quarter that ended in Jun. 2026 was ₹2,071.8 Mil. Therefore, Shree Ganesh Remedies's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 2.16%.
The historical rank and industry rank for Shree Ganesh Remedies's Return-on-Tangible-Asset or its related term are showing as below:
BOM:540737'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.69 Med: 16.37 Max: 20.59
Current: 7.69
During the past 13 years, Shree Ganesh Remedies's highest Return-on-Tangible-Asset was 20.59%. The lowest was 7.69%. And the median was 16.37%.
BOM:540737's Return-on-Tangible-Asset is ranked better than 70.21% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.79
vs BOM:540737: 7.69
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Shree Ganesh Remedies Return-on-Tangible-Asset Related Terms
Shree Ganesh Remedies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Shree Ganesh Remedies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540737 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shree Ganesh Remedies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Ganesh Remedies Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shree Ganesh Remedies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Shree Ganesh Remedies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.16% mean?
Shree Ganesh Remedies (BOM:540737) has a Return-on-Tangible-Asset of 2.16% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shree Ganesh Remedies and its competitors. This is 87% below median its historical median of 16.37. Over the past decade, Shree Ganesh Remedies' Return-on-Tangible-Asset has ranged from 7.69 to 20.59. According to the industry distribution chart, Shree Ganesh Remedies ranks #300 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is Shree Ganesh Remedies' Return-on-Tangible-Asset too high?
Shree Ganesh Remedies' current Return-on-Tangible-Asset of 2.16% is 87% below median its 10-year median of 16.37. Over the past 10 years, this metric has ranged from a low of 7.69 to a high of 20.59. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.79. Shree Ganesh Remedies' value of 2.16% is 22.6% below this industry median. Based on the distribution chart, Shree Ganesh Remedies ranks #300 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shree Ganesh Remedies has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shree Ganesh Remedies' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shree Ganesh Remedies ranks #300 out of 1007 companies for Return-on-Tangible-Asset. This puts Shree Ganesh Remedies in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.79. Shree Ganesh Remedies' value of 2.16% is 22.6% below this benchmark. Historically, Shree Ganesh Remedies' own Return-on-Tangible-Asset has ranged from 7.69 to 20.59 over the past decade. While the company's 10-year median is 16.37 vs. the industry median of 2.79, Shree Ganesh Remedies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.79, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shree Ganesh Remedies's current Return-on-Tangible-Asset of 2.16% is 22.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shree Ganesh Remedies and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Ganesh Remedies's current Return-on-Tangible-Asset is 2.16%, which is 87% below median its own 10-year median of 16.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Ganesh Remedies stock overvalued right now?
Based on GuruFocus' analysis, Shree Ganesh Remedies (BOM:540737) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹554.11, compared to a current price of ₹686.50 — trading 23.9% above its estimated fair value. The current Return-on-Tangible-Asset is 2.16%, which is 87% below median its 10-year median of 16.37 and 22.6% below the Drug Manufacturers industry median of 2.79. Shree Ganesh Remedies' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Shree Ganesh Remedies (BOM:540737), the current Return-on-Tangible-Asset is 2.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Ganesh Remedies (BOM:540737) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Ganesh Remedies stock appears to be overvalued.
The current stock price of ₹686.50 is trading 23.9% above its estimated GF Value™ of ₹554.11.
GuruFocus considers Shree Ganesh Remedies to be Modestly Overvalued.
Key valuation signals for BOM:540737:
Return-on-Tangible-Asset: 2.16% (87% below median its 10-year median of 16.37)
GF Value™: ₹554.11 vs. price of ₹686.50 (23.9% above fair value)
Industry Position: 22.6% below the Drug Manufacturers median (#300 of 1007)
No single metric tells the full story. See the BOM:540737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Ganesh Remedies Ltd manufactures drug intermediates, chemicals, and specialty fine chemicals for the pharmaceutical industry. The company offers pharmaceutical and specialty chemical products, including Trityl chloride, Furoyl chloride, and Dinitolmide. The company's business falls under the primary segment of Bulk Drug Intermediaries.
84GF Score
Get the complete analysis for BOM:540737
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540737 has been successfully added to your 
